Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse MKT  >  CorMedix Inc.    CRMD

CORMEDIX INC.

(CRMD)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
06/19/2019 06/20/2019 06/21/2019 06/24/2019 06/25/2019 Date
7.6(c) 7.88(c) 7.97(c) 7.77(c) 7.71(c) Last
196 089 288 752 177 836 381 933 273 034 Volume
+5.56% +3.68% +1.14% -2.51% -0.77% Change
More quotes
Financials (USD)
Sales 2015 0,54 M
EBIT 2015 -5,90 M
Net income 2015 -15,1 M
Debt 2015 -
Yield 2015 -
Sales 2016 0,66 M
EBIT 2016 -0,88 M
Net income 2016 -18,7 M
Debt 2016 -
Yield 2016 -
P/E ratio 2015 -
P/E ratio 2016
Capi. / Sales2015 345x
Capi. / Sales2016 281x
Capitalization 185 M
More Financials
Company
CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Surperformance© ratings of CorMedix Inc.
Trading Rating : - Investor Rating :
More Ratings
Latest news on CORMEDIX INC.
06/10CorMedix Inc. to Ring NYSE Closing Bell on Monday, June 10
GL
05/16CORMEDIX INC. : to Present at the 20th Annual B. Riley FBR Institutional Investo..
AQ
05/13CORMEDIX : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
05/13CORMEDIX : 1Q Earnings Snapshot
AQ
05/13CORMEDIX INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
05/13CORMEDIX INC. : Reports First Quarter 2019 Financial Results and Provides Busin..
AQ
05/10CORMEDIX : Announces Presentation of LOCK-IT-100 Study Results at National Kidne..
AQ
05/06CORMEDIX INC. : to Report First Quarter 2019 Financial Results and Provide a Cor..
AQ
04/22CorMedix Announces Online Pre-Clinical Abstract at the Upcoming Annual Meetin..
GL
04/17CORMEDIX INC. : Other Events (form 8-K)
AQ
More news
Sector news : Specialty & Advanced Pharmaceuticals
06/25AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan
RE
06/25Nestlé, Novartis Among Companies at Risk of London Trading Ban -- 2nd Update
DJ
06/25AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan
RE
06/25ABBVIE : S&P Puts AbbVie on Watch Negative After Allergan Deal
DJ
06/25Nestlé, Novartis at Risk of London Trading Ban -- Update
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Chart CORMEDIX INC.
Duration : Period :
CorMedix Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 6,75 $
Spread / Average Target -13%
EPS Revisions
Managers
NameTitle
Mohammed Khoso Baluch Chief Executive Officer & Director
Myron Kaplan Chairman
Robert W. Cook Chief Financial Officer
Antony E. Pfaffle Secretary & Chief Scientific Officer
John L. Armstrong EVP-Technical Operations & Head-Human Resources
Sector and Competitors
1st jan.Capitalization (M$)
CORMEDIX INC.502.33%141
WUXI APPTEC CO LTD11.76%13 352
MERCK KGAA3.25%12 839
KYOWA HAKKO KIRIN CO LTD-2.71%10 079
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD32.61%9 399
JAZZ PHARMACEUTICALS PLC5.93%7 204